Depo-Provera® Treatment Does Not Abrogate Protection from Intravenous SIV Challenge in Female Macaques Immunized with an Attenuated AIDS Virus
Figure 2
Changes in peripheral CD4+ T cell populations after IV SIVmac239 challenge.
(A) Number of CD4+ T cells, and (B) the percentage of CD4+ CD95+ T cells in blood. (λ) Naïve control macaques (n = 7), (○) SHIV-immunized macaques (n = 5) and (5) Depo-Provera® SHIV-immunized macaques (n = 6). The number of CD4+ T cells (p = 0.0007) and the percentages of CD4+ CD95+ T cell (p<0.0001) were significantly higher (Friedman test) in the Depo-Provera®-treated, SHIV-immunized macaques than in the naïve control group.